Prevalence of HRR-related genes mutations and prognosis in metastatic castration resistant prostate cancer (mCRPC) patients in real world setting

Trial Identifier: D081LR00002
Sponsor: AstraZeneca
NCTID:: NCT04425200
Start Date: July 2020
Primary Completion Date: December 2020
Study Completion Date: December 2020
Condition: Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan, Aichi Nagoya, Aichi, Japan
Japan, Aomori Hirosaki, Aomori, Japan
Japan, Chiba Chiba, Japan
Japan, Chiba Kashiwa, Chiba, Japan
Japan, Ehime Toon, Ehime, Japan
Japan, Gifu Gifu, Japan
Japan, Hiroshima Kure, Hiroshima, Japan
Japan, Hokkaido Hakodate, Hokkaido, Japan
Japan, Hokkaido Sapporo, Hokkaido, Japan
Japan, Hyogo Kobe, Hyogo, Japan
Japan, Ibaraki Tsukuba, Ibaraki, Japan
Japan, Ishikawa Kanazawa, Ishikawa, Japan
Japan, Kagawa Miki, Kagawa, Japan
Japan, Kanagawa Yokohama, Kanagawa, Japan
Japan, Kyoto Kyoto, Japan
Japan, Miyazaki Miyazaki, Japan
Japan, Nara Kashihara, Nara, Japan
Japan, Okayama Okayama, Japan
Japan, Osaka Osakasayama, Osaka, Japan
Japan, Saitama Kawagoe, Saitama, Japan
Japan, Tottori Yonago, Tottori, Japan
Japan, Yamaguchi Ube, Yamaguchi, Japan